Literature DB >> 11751749

Prime-boost immunization generates a high frequency, high-avidity CD8(+) cytotoxic T lymphocyte population.

Marie J Estcourt1, Alistair J Ramsay, Andrew Brooks, Scott A Thomson, Coralie J Medveckzy, Ian A Ramshaw.   

Abstract

Development and expansion of high-avidity T cell populations may be important for the success of immunization strategies against HIV and other pathogens that have presented major problems for vaccine development. We have used tetrameric-MHC complexes ex vivo and lytic assays to show that 'prime-boost' immunization with DNA vaccines and recombinant poxvirus vectors generates high frequencies of cytotoxic T lymphocytes (CTL) that recognize target cells expressing very low levels of specific antigen. These cells persist for at least 6 months at levels representing approximately 10% of the CD8(+) T cell population. Using a novel in vivo assay, we also found that prime-boost immunized animals were capable of eliminating target cells expressing 10- to 100-fold less immunogenic peptide than mice given either vector alone. In addition, viral challenge led to rapid expansion of CTL effectors in prime-boost groups, to levels representing >30% of total CD8(+) T cell numbers. Strategies that generate specific T cells of high avidity, optimizing early detection of infected cells, offer new hope for effective prophylaxis and immunotherapy.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11751749     DOI: 10.1093/intimm/14.1.31

Source DB:  PubMed          Journal:  Int Immunol        ISSN: 0953-8178            Impact factor:   4.823


  40 in total

Review 1.  New approaches to design HIV-1 T-cell vaccines.

Authors:  Hélène Perrin; Glenda Canderan; Rafick-Pierre Sékaly; Lydie Trautmann
Journal:  Curr Opin HIV AIDS       Date:  2010-09       Impact factor: 4.283

2.  Biomaterials at the interface of nano- and micro-scale vector-cellular interactions in genetic vaccine design.

Authors:  Charles H Jones; Anders P Hakansson; Blaine A Pfeifer
Journal:  J Mater Chem B       Date:  2014-09-12       Impact factor: 6.331

3.  Low Antigen Dose in Adjuvant-Based Vaccination Selectively Induces CD4 T Cells with Enhanced Functional Avidity and Protective Efficacy.

Authors:  Rolf Billeskov; Yichuan Wang; Shahram Solaymani-Mohammadi; Blake Frey; Shweta Kulkarni; Peter Andersen; Else Marie Agger; Yongjun Sui; Jay A Berzofsky
Journal:  J Immunol       Date:  2017-03-27       Impact factor: 5.422

4.  Systemic priming-boosting immunization with a trivalent plasmid DNA and inactivated murine cytomegalovirus (MCMV) vaccine provides long-term protection against viral replication following systemic or mucosal MCMV challenge.

Authors:  Christopher S Morello; Ming Ye; Stephanie Hung; Laura A Kelley; Deborah H Spector
Journal:  J Virol       Date:  2005-01       Impact factor: 5.103

5.  Gene-based neonatal immune priming potentiates a mucosal adenoviral vaccine encoding mycobacterial Ag85B.

Authors:  Guixiang Dai; Hamada F Rady; Weitao Huang; Judd E Shellito; Carol Mason; Alistair J Ramsay
Journal:  Vaccine       Date:  2016-11-04       Impact factor: 3.641

6.  CD40 ligand enhances immunogenicity of vector-based vaccines in immunocompetent and CD4+ T cell deficient individuals.

Authors:  Matthew W Auten; Weitao Huang; Guixiang Dai; Alistair J Ramsay
Journal:  Vaccine       Date:  2012-02-18       Impact factor: 3.641

7.  Boosting functional avidity of CD8+ T cells by vaccinia virus vaccination depends on intrinsic T-cell MyD88 expression but not the inflammatory milieu.

Authors:  Zhidong Hu; Jing Wang; Yanmin Wan; Lingyan Zhu; Xiaonan Ren; Sugan Qiu; Yanqin Ren; Songhua Yuan; Xiangqing Ding; Jian Chen; Chenli Qiu; Jun Sun; Xiaoyan Zhang; Jim Xiang; Chao Qiu; Jianqing Xu
Journal:  J Virol       Date:  2014-02-19       Impact factor: 5.103

8.  Multigene DNA priming-boosting vaccines protect macaques from acute CD4+-T-cell depletion after simian-human immunodeficiency virus SHIV89.6P mucosal challenge.

Authors:  N A Doria-Rose; C Ohlen; P Polacino; C C Pierce; M T Hensel; L Kuller; T Mulvania; D Anderson; P D Greenberg; S-L Hu; N L Haigwood
Journal:  J Virol       Date:  2003-11       Impact factor: 5.103

Review 9.  DNA vaccines: developing new strategies against cancer.

Authors:  Daniela Fioretti; Sandra Iurescia; Vito Michele Fazio; Monica Rinaldi
Journal:  J Biomed Biotechnol       Date:  2010-03-28

10.  Heterologous Prime-Boost HIV-1 Vaccination Regimens in Pre-Clinical and Clinical Trials.

Authors:  Scott A Brown; Sherri L Surman; Robert Sealy; Bart G Jones; Karen S Slobod; Kristen Branum; Timothy D Lockey; Nanna Howlett; Pamela Freiden; Patricia Flynn; Julia L Hurwitz
Journal:  Viruses       Date:  2010-02-01       Impact factor: 5.048

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.